EWA
RYTM icon

Evolution Wealth Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Evolution Wealth Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-213
Closed -$3K – 533
2021
Q3 		$3K Sell
213
-325
-60% -$4.96K ﹤0.01% 620
2021
Q2 		$11K Hold
538
– – ﹤0.01% 396
2021
Q1 		$11K Sell
538
-199
-27% -$5.77K ﹤0.01% 405
2020
Q4 		$22K Sell
737
-95
-11% -$2.41K 0.01% 257
2020
Q3 		$18K Hold
832
– – ﹤0.01% 282
2020
Q2 		$19K Hold
832
– – 0.01% 207
2020
Q1 		$13K Buy
832
+70
+9% +$1.25K 0.01% 190
2019
Q4 		$17K Buy
762
+710
+1,365% +$15.8K ﹤0.01% 246
2019
Q3 		$1K Sell
52
-511
-91% -$11K ﹤0.01% 465
2019
Q2 		$12K Buy
+563
New +$14.2K 0.01% 163

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Evolution Wealth Advisors's RYTM Position: Q4 2021 in Review

Evolution Wealth Advisors sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2021, closing a stake of 213 shares — an estimated $3K sold.

Evolution Wealth Advisors first reported a position in RYTM in Q2 2019 and held it in 10 quarters. The position peaked at $22K in Q4 2020. 98 funds tracked by Wall St. Rank hold RYTM as of Q4 2021.

  • Evolution Wealth Advisors reported no remaining Rhythm Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Evolution Wealth Advisors sold 213 Rhythm Pharmaceuticals shares in Q4 2021, an estimated $3K.
  • Evolution Wealth Advisors first reported a position in Rhythm Pharmaceuticals in Q2 2019 and held it in 10 quarters.
  • Evolution Wealth Advisors's Rhythm Pharmaceuticals position peaked at $22K in Q4 2020.
  • 98 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2021.

Based on Evolution Wealth Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.